Clinical benefit of cancer drugs approved in Switzerland 2010-2019
Adam, Roman (Faculty of Medicine. University of Basel)
Tibau Martorell, Ariadna (Institut d'Investigació Biomèdica Sant Pau)
Valiente, C.M. (Institut d'Investigació Biomèdica Sant Pau)
Šeruga, Bostjan (Univerza V Ljubljani)
Ocaña, Alberto (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos)
Amir, Eitan (University of Toronto, Canada)
Templeton, Arnoud (St. Clara Research Ltd.)

Date:	2022
Abstract:	Background It is unknown to what extent cancer drugs approved in Switzerland by the Swissmedic fulfil criteria of clinical benefit according to the European Society of Medical Oncology Magnitude of Clinical Benefit Scale version 1. 1 (ESMO-MCBS), the American Society of Clinical Oncology Value Framework version 2 (ASCO-VF) and the Swiss OLUtool v2 (OLUtool). Patients and methods An electronic search identified studies that led to marketing authorisations in Switzerland 2010-2019. Studies were evaluated according to ESMO-MCBS, ASCO-VF and OLUtool. Substantial benefit for ESMO-MCBS, was defined as a grade A or B for (neo)adjuvant intent and 4 or 5 for palliative intent. For ASCO-VF and OLUtool clinical benefit was defined as score ≥45 and A or B, respectively. Concordance between the frameworks was calculated with Cohen's Kappa (κ). Factors associated with clinical benefit were evaluated by logistic regression. Results In the study period, 48 drugs were approved for 92 evaluable indications, based on 100 studies. Ratings for ESMO-MCBS, ASCO-VF and OLUtool could be performed for 100, 86, and 97 studies, respectively. Overall, 39 (39%), 44 (51%), 45 (46%) of the studies showed substantial clinical benefit according to ESMO-MCBS v1. 1, ASCO-VF, OLUtool criteria, respectively. There was fair concordance between ESMO-MCBS and ASCO-VF in the palliative setting (κ = 0. 31, P = 0. 004) and moderate concordance between ESMO-MCBS and OLUtool (κ = 0. 41, P<0. 001). There was no significant concordance between ASCO-VF and OLUtool (κ = 0. 18, P = 0. 12). Factors associated with substantial clinical benefit in multivariable analysis were HRQoL benefit reported as secondary outcome for ESMO-MCBS and the ASCO-VF and blinded studies for OLUtool. Conclusions At the time of approval, only around half of the trials supporting marketing authorisation of recently approved cancer drugs in Switzerland meet the criteria for substantial clinical benefit when evaluated with ESMO-MCBS, ASCO-VF or OLUtool. There was at best only moderate concordance between the grading systems.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Antineoplastic Agents ; Humans ; Medical Oncology ; Neoplasms ; Quality of Life ; Switzerland
Published in:	PloS one, Vol. 17 Núm. 6 June (june 2022) , p. e0268545, ISSN 1932-6203

DOI: 10.1371/journal.pone.0268545
PMID: 35687539

13 p, 1.7 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles